SEOM-GEICO clinical guidelines on endometrial cancer (2021)

• María Pilar Barretina-Ginesta ^[4] ; María Quindós ^[5] ; Jesús Damián Alarcón ^[1] ; Carmen Esteban ^[6] ; Lydia Gaba ^[2] ; César Gómez ^[7] ; José Alejandro Pérez Fidalgo ^[8] ; Ignacio Romero ^[3] ; Ana Santaballa ^[9] ; María Jesús Rubio-Pérez ^[10]
  1. [1] Hospital Universitario Son Espases

     Hospital Universitario Son Espases

     Palma de Mallorca, España

     
  2. [2] Hospital Clinic Barcelona

     Hospital Clinic Barcelona

     Barcelona, España

     
  3. [3] Instituto Valenciano de Oncologia

     Instituto Valenciano de Oncologia

     Valencia, España

     
  4. [4] Medical Oncology Department, Institut Català d’Oncologia (ICO), Department of Medical Sciences, Girona Biomedical Research Institute (IDIBGI). Department of Medical Sciences, Medical School University of Girona (UdG), Girona, Spain
  5. [5] Medical Oncology Department, Complexo Hospitalario Universitario de A Coruña. Biomedical Research Institute (INIBIC), A Coruña, Spain
  6. [6] Medical Oncology Department, Complejo Hospitalario de Toledo, Toledo, Spain
  7. [7] Department of Medical Oncology, Infanta Sofía and Henares Hospitals Foundation for Biomedical Research and Innovation (FIIB HUIS HHEN), Infanta Sofía University Hospital, Madrid, Spain
  8. [8] Medical Oncology Department, Hospital Clínico Universitario of Valencia. Biomedical Research Institute INCLIVA. CIBERONC, Valencia, Spain
  9. [9] Medical Oncology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain
  10. [10] Medical Oncology Department, Hospital Universitario Reina Sofía. University of Córdoba, Córdoba, Spain

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 24, Nº. 4 (April), 2022, págs. 625-634
• Idioma: inglés
• Enlaces
  • Texto completo (pdf)
• Dialnet Métricas: 1 Cita
• Resumen

  • Endometrial cancer (EC) is the second most common gynecological malignancy worldwide, the first in developed countries [Sung et al. in CA Cancer J Clin 71:209–249, 2021]. Although a majority is diagnosed at an early stage with a low risk of relapse, an important proportion of patients will relapse. Better knowledge of molecular abnormalities is crucial to identify high-risk groups in early stages as well as for recurrent or metastatic disease for whom adjuvant treatment must be personalized. The objective of this guide is to summarize the current evidence for the diagnosis, treatment, and follow-up of EC, and to provide evidence-based recommendations for clinical practice.